These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32399096)

  • 1. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.
    Borgio JF; Alsuwat HS; Al Otaibi WM; Ibrahim AM; Almandil NB; Al Asoom LI; Salahuddin M; Kamaraj B; AbdulAzeez S
    Arch Med Sci; 2020; 16(3):508-518. PubMed ID: 32399096
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gurung AB
    Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.
    Adedeji AO; Singh K; Calcaterra NE; DeDiego ML; Enjuanes L; Weiss S; Sarafianos SG
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4718-28. PubMed ID: 22733076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Zafirlukast as a novel SARS-CoV-2 helicase inhibitor using in silico modelling and a FRET-based assay.
    Mehyar N; Mashhour A; Islam I; Alhadrami HA; Tolah AM; Alghanem B; Alkhaldi S; Somaie BA; Al Ghobain M; Alobaida Y; Alaskar AS; Boudjelal M
    SAR QSAR Environ Res; 2021 Dec; 32(12):963-983. PubMed ID: 34818959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
    Abidi SH; Almansour NM; Amerzhanov D; Allemailem KS; Rafaqat W; Ibrahim MAA; la Fleur P; Lukac M; Ali S
    Sci Rep; 2021 May; 11(1):10290. PubMed ID: 33986405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19.
    Mujwar S; Sun L; Fidan O
    J Food Biochem; 2022 Sep; 46(9):e14219. PubMed ID: 35545850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2.
    Azeez SA; Alhashim ZG; Al Otaibi WM; Alsuwat HS; Ibrahim AM; Almandil NB; Borgio JF
    Arch Med Sci; 2020; 16(3):497-507. PubMed ID: 32399095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach.
    Romeo I; Ambrosio FA; Costa G; Corona A; Alkhatib M; Salpini R; Lemme S; Vergni D; Svicher V; Santoro MM; Tramontano E; Ceccherini-Silberstein F; Artese A; Alcaro S
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
    Ugurel OM; Mutlu O; Sariyer E; Kocer S; Ugurel E; Inci TG; Ata O; Turgut-Balik D
    Int J Biol Macromol; 2020 Nov; 163():1687-1696. PubMed ID: 32980406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
    Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
    Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
    Purohit P; Dash JJ; Muya JT; Meher BR
    J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.